CD19 and B-cell non-Hodgkin lymphoma: In this respect, a clinical study of third- versus second-generation CD19 CAR-T cells for B cell non-Hodgkin lymphoma identified better persistence and up to 40-fold higher expansion with the third-generation CD19 CAR-T cells.33